Teglutik is a medication primarily used in the management and treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord, leading to muscle weakness and, eventually, severe disability. Teglutik contains the active ingredient riluzole, which works by modulating glutamate signaling in the brain. Glutamate is a neurotransmitter that, in excessive amounts, can contribute to the death of nerve cells. By reducing the release of glutamate, Teglutik can help slow down the progression of ALS symptoms, potentially improving quality of life and increasing survival time for patients. It is notable for its liquid formulation, making it easier to administer to ALS patients who may have difficulty swallowing pills.